The purpose of this study is to obtain a preliminary assessment of the antiviral activity and tolerability of simplified Kaletra dual agent therapy as initial treatment for HIV infection, relative to a Kaletra three drug standard of care reference arm.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
152
TDF 300mg QD for 72 wks
LPV/rSGC 400/100mg BID + 2 nucleoside RTIs as prescribed by the Investigator for 72 wks
Global Medical Information-Abbott
Abbott Park, Illinois, United States
Antiviral efficacy by HIV RNA
Time frame: 72 wks
Incidence of adverse events
Time frame: 72 wks
Adherence and quality of life
Time frame: 72 wks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.